Abstract: The present invention concerns a method for the prevention and/or treatment of an activation-induced deaminase (AID)-associated disease in a subject in need thereof, said method comprising administering an effective amount of an uracil-DNA glycosylase (UNG) inhibitor, or a composition comprising the inhibitor, and a pharmaceutically acceptable carrier, to a subject having pathogenic cells expressing AID, uracil-DNA glycosylase (UNG) and mismatch repair pathway (MMR). Also provided are kits comprising an UNG inhibitor, methods of stratifying a subject having an AID-associated disease, uses and compositions for use of the UNG inhibitor.

Abstract: A method for stratifying a subject, said method comprising: measuring the AID expression and/or activity in a first sample of the subject, and comparing said expression and/or activity to a reference AID expression and/or activity, wherein an AID expression and/or activity in the first sample of the subject that is higher than the reference AID expression and/or activity is indicative that the subject would benefit from a treatment with at least one Heat Shock Protein 90 (Hsp90) inhibitor.